Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00376454 · ClinicalTrials.gov registry record · Phase 2
The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
NCT00376454 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 113 participants.
The verdict
NCT00376454, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the analgesic effect of GW493838 in patients with post-herpetic neuralgia or peripheral nerve injury caused by trauma or surgery.
Interventions
- DRUG GW493838
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2002-11 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00376454
The ClinicalTrials.gov registry entry for NCT00376454 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GW493838 is the first listed.
NCT00376454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00376454 about?
NCT00376454 is a clinical study titled "The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain". The purpose of this study was to determine the analgesic effect of GW493838 in patients with post-herpetic neuralgia or peripheral nerve injury caused by trauma or surgery.
What is the current status of trial NCT00376454?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2002-11. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00376454?
The interventions under investigation include: GW493838 (DRUG).
Who is sponsoring clinical trial NCT00376454?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.